285 related articles for article (PubMed ID: 31939441)
1. Correlations between maximum standardized uptake value measured via
Li H; Wang X; Zhang L; Yi X; Qiao Y; Jin Q
J Cancer Res Ther; 2019; 15(7):1581-1588. PubMed ID: 31939441
[TBL] [Abstract][Full Text] [Related]
2. [Correlation and Influencing Factors of SUVmax and Ki-67 in Non-Hodgkin Lymphoma].
Li J; Zhao M; Yuan L; Liu Y; Ma N
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Feb; 30(1):136-140. PubMed ID: 35123616
[TBL] [Abstract][Full Text] [Related]
3. Value of
Alobthani G; Romanov V; Isohashi K; Matsunaga K; Watabe T; Kato H; Tatsumi M; Shimosegawa E; Hatazawa J
Hell J Nucl Med; 2018; 21(1):7-14. PubMed ID: 29550841
[TBL] [Abstract][Full Text] [Related]
4. [Metabolic activity measured by ¹⁸F-FDG PET/CT in newly diagnosed patients with non-Hodgkin lymphoma: correlation with immunophenotype].
Zhang J; Wang R; Fan Y; Fu Z; Zhang X; Liao X; Liu M; Kang L; Cui Y; Wang Y; Jiang Q
Zhonghua Yi Xue Za Zhi; 2014 Sep; 94(33):2576-9. PubMed ID: 25511487
[TBL] [Abstract][Full Text] [Related]
5. Nomograms based on SUVmax of
Li H; Shao G; Zhang Y; Chen X; Du C; Wang K; Gao Z
Cancer Imaging; 2021 Jan; 21(1):9. PubMed ID: 33419476
[TBL] [Abstract][Full Text] [Related]
6. Standardized uptake value for (18)F-fluorodeoxyglucose is correlated with a high International Prognostic Index and the presence of extranodal involvement in patients with diffuse large B-cell lymphoma.
Akkas BE; Vural GU
Rev Esp Med Nucl Imagen Mol; 2014; 33(3):148-52. PubMed ID: 24094371
[TBL] [Abstract][Full Text] [Related]
7. Comparison of clinical and PET-derived prognostic factors in patients with non-Hodgkin lymphoma: a special emphasis on bone marrow involvement.
Kupik O; Akin S; Tuncel M; Eren G; Türker A; Kars A; Erbaş B
Nucl Med Commun; 2020 Jun; 41(6):540-549. PubMed ID: 32209829
[TBL] [Abstract][Full Text] [Related]
8. Prognostic role of baseline
Albano D; Bosio G; Camoni L; Farina M; Re A; Tucci A; Giubbini R; Bertagna F
Hematol Oncol; 2019 Feb; 37(1):39-46. PubMed ID: 30299563
[TBL] [Abstract][Full Text] [Related]
9. (18)F-fluorodeoxyglucose positron emission tomography/computed tomography comparison of gastric lymphoma and gastric carcinoma.
Li XF; Fu Q; Dong YW; Liu JJ; Song XY; Dai D; Zuo C; Xu WG
World J Gastroenterol; 2016 Sep; 22(34):7787-96. PubMed ID: 27678362
[TBL] [Abstract][Full Text] [Related]
10. [The value of (18)F-FDG PET-CT imaging in predicting the malignant potential of GIST].
Li SX; Tang MD; Lin DY; Liu DJ; Lyu QH; Zhang JP; Cai ZH
Zhonghua Zhong Liu Za Zhi; 2017 Nov; 39(11):821-827. PubMed ID: 29151288
[No Abstract] [Full Text] [Related]
11. Clinical usefulness of FDG-PET/CT for the evaluation of various types of adult T-cell leukemia.
Nakachi S; Okada M; Morishima S; Agarie Y; Kitamura S; Uchibori S; Tomori S; Hanashiro T; Shimabukuro N; Tamaki K; Tedokon I; Morichika K; Nishi Y; Tomoyose T; Karube K; Fukushima T; Murayama S; Masuzaki H
Hematology; 2017 Oct; 22(9):536-543. PubMed ID: 28397608
[TBL] [Abstract][Full Text] [Related]
12. Preliminary clinical assessment of dynamic 18F-fluorodeoxyglucose positron-emission tomography/computed tomography for evaluating the clinicopathological grade in patients with non-Hodgkin's lymphoma: a prospective study.
Shinya T; Otomi Y; Dimitrakopoulou-Strauss A; Kubo M; Kondo M; Otomo M; Terazawa K; Bando Y; Harada M
Nucl Med Commun; 2020 Jan; 41(1):26-33. PubMed ID: 31800508
[TBL] [Abstract][Full Text] [Related]
13. 18F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance in Lymphoma: Comparison With 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography and With the Addition of Magnetic Resonance Diffusion-Weighted Imaging.
Giraudo C; Raderer M; Karanikas G; Weber M; Kiesewetter B; Dolak W; Simonitsch-Klupp I; Mayerhoefer ME
Invest Radiol; 2016 Mar; 51(3):163-9. PubMed ID: 26784400
[TBL] [Abstract][Full Text] [Related]
14. Lactate dehydrogenase levels and 18F-FDG PET/CT metrics differentiate between mediastinal Hodgkin's lymphoma and primary mediastinal B-cell lymphoma.
Alkhawtani RHM; Noordzij W; Glaudemans AWJM; van Rijn RS; van der Galiën HT; Balink H; Nijland M; Adams HJA; Huls G; van Meerten T; Kwee TC
Nucl Med Commun; 2018 Jun; 39(6):572-578. PubMed ID: 29672465
[TBL] [Abstract][Full Text] [Related]
15. SUV on dual-phase FDG PET/CT correlates with the Ki-67 proliferation index in patients with newly diagnosed non-Hodgkin lymphoma.
Chang CC; Cho SF; Chen YW; Tu HP; Lin CY; Chang CS
Clin Nucl Med; 2012 Aug; 37(8):e189-95. PubMed ID: 22785526
[TBL] [Abstract][Full Text] [Related]
16. Correlation between semiquantitative and volumetric 18F-FDG PET/computed tomography parameters and Ki-67 expression in breast cancer.
Mohamadien NRA; Sayed MHM
Nucl Med Commun; 2021 Jun; 42(6):656-664. PubMed ID: 33560720
[TBL] [Abstract][Full Text] [Related]
17. Value of contrast-enhanced ultrasound and PET/CT in assessment of extramedullary lymphoma.
Jiang W; Xue H; Wang Q; Zhang X; Wang Z; Zhao C
Eur J Radiol; 2018 Feb; 99():88-93. PubMed ID: 29362156
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of SUVmax measured by pretreatment 18F-FDG PET/CT in patients with primary gastric lymphoma.
Hwang JP; Lim I; Byun BH; Kim BI; Choi CW; Lim SM
Nucl Med Commun; 2016 Dec; 37(12):1267-1272. PubMed ID: 27482643
[TBL] [Abstract][Full Text] [Related]
19. The correlation of prognostic biomarkers (Ki-67, Bcl-2, HIF-1α, cyclin D1) with metabolic tumor volume measured by F-FDG PET/CT inlaryngeal cancer.
Eryilmaz A; Cengiz A; Basal Y; Meteoglu I; Omurlu IK; Yurekli Y
J Cancer Res Ther; 2018; 14(5):994-998. PubMed ID: 30197337
[TBL] [Abstract][Full Text] [Related]
20. [Correlation of ¹⁸F-FDG uptake with tumor-proliferating antigen Ki-67 expression in aggressive lymphoma].
Liang Y; Wu N; Fang Y; Huang WT; Zhang H; Zheng R; Zhang WJ; Liu Y; Li XM
Zhonghua Zhong Liu Za Zhi; 2013 May; 35(5):356-60. PubMed ID: 24054012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
